NextCure
IPO News: Filed S-1: NextCure Files $86.3mm IPO
NextCure

NextCure

NASDAQ:  NXTC

Size (mm):  $86.3

Bookrunners:  MS | BAML | PJ

Major Holders: OrbiMed Private Investments | Canaan X L.P | Pfizer | Lilly Asia Ventures | HH NCure Holdings | Quan Venture Fund | Eli Lilly and Company

Description: NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.

Note: Emerging Growth Company

Reference Link: S-1